National Health (Originator Brand) Amendment Determination 2016 (No. 7) (PB 89 of 2016) (Cth)

PB 89 of 2016

National Health (Originator Brand) Amendment Determination 2016 (No. 7)

National Health Act 1953

I, ANDREW RINTOUL, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated        28   September 2016

______________________________________

ANDREW RINTOUL
Assistant Secretary (Acting)
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health

1. Name of Determination

   (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2016 (No. 7).

   (2)     This Determination may also be cited as PB 89 of 2016.

2. Commencement

   This Determination commences on 1 October 2016.

3. Amendments to PB 100 of 2015

   Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1, (after table item 110)

insert:

110A Imatinib Glivec